SYNERGY™ XD H7493941812450Recalls & reported problems
Boston Scientific Corporation · Everolimus-Eluting Platinum Chromium Coronary Stent System · Class 3 · Implant
All models of SYNERGY XD (65)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 3
- Deaths reported
- 0
- Injuries reported
- 2
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 3 adverse event reports that list this exact device (DI 08714729981183), received between Jul 20, 2021 and Aug 5, 2022 — classified as 2 injuries, 1 malfunction.
The most frequently reported specific device problem is “Failure to Advance” (2 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Failure to Advance2
- Activation Failure1
- Difficult to Remove1
- Material Deformation1
- Migration1
Patient problems
- No Clinical Signs, Symptoms or Conditions2
- Insufficient Information1
Recent adverse event reports
The 3 most recent of 3 reports, in the reporter's own words as published by the FDA.
InjuryAug 5, 2022Failure to Advance; Failure to Advance
IT WAS REPORTED THAT AN ADVERSE PATIENT EVENT OCCURRED. A 4.50 X 12MM SYNERGY XD DRUG-ELUTING STENT WAS ADVANCED BUT FAILED TO CROSS THE LESION. THE INABILITY TO CROSS THE LESION CAUSED A SIGNIFICANT DELAY TO THE PROCEDURE THAT RESULTED IN AN ADVERSE PATIENT EVENT. DESPITE MULTIPLE EFFORTS, NO FURTHER INFORMATION WAS ABLE TO BE OBTAINED.
Patient problems: Insufficient Information
MAUDE report 15179047 ↗InjuryMay 26, 2022Difficult to Remove; Activation Failure; Migration; Difficult to Remove; Activation Failure; Migration
IT WAS REPORTED THAT REMOVAL DIFFICULTY, STENT NOT FULLY EXPANDED, AND STENT MIGRATION OCCURRED. THE 80% STENOSED TARGET LESION WAS LOCATED IN THE MODERATE TO SEVERELY TORTUOUS AND NON- TO MILDLY CALCIFIED PROXIMAL CIRCUMFLEX ARTERY. NO LESION PREPARATION WAS PERFORMED. A 4.50 X 16MM SYNERGY XD DRUG-ELUTING STENT (DES) WAS ADVANCED FOR TREATMENT. THE STENT WAS INFLATED AT 11 ATMOSPHERES (ATM) FOR 20 SECONDS AND APPEARED NORMAL AND EXPANDED. THE STENT WAS PLACED; HOWEVER, THE STENT SHIFTED DISTAL TO THE LESION. ANOTHER 4.50 X 12MM SYNERGY XD DES WAS ADVANCED TO COVER THE MISSED LESION AND WAS INFLATED AT 12 ATM FOR 20 SECONDS. PRIOR TO REMOVAL, THE BALLOON WAS DEFLATED; HOWEVER, WHEN THE PHYSICIAN TRIED TO REMOVE THE BALLOON CATHETER, THERE WAS RESISTANCE. THE INFLATION DEVICE WAS CHECKED TO CONFIRM IT WAS DOWN AND THE DOCTOR PULLED TO GET THE CATHETER OUT. AFTER REMOVAL, IT WAS NOTICED THAT THE STENT ITSELF PULLED BACK INTO THE LEFT MAIN ARTERY, AND THE DISTAL EDGE OF THE STENT APPEARED TO BE NOT FULLY EXPANDED AND ALSO WAS NOW PROXIMAL TO THE LESION. SUBSEQUENTLY, ANOTHER 5.0X12 SYNERGY XD DES WAS ADVANCED AND INFLATED AT 16 ATMOSPHERES FOR 10 SECONDS TO PUT BETWEEN THE 2 STENTS A
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 14504002 ↗MalfunctionJul 20, 2021Failure to Advance; Material Deformation; Failure to Advance; Material Deformation
IT WAS REPORTED THAT STENT DAMAGE OCCURRED. THE TARGET LESION WAS LOCATED IN A SAPHENOUS VEIN GRAFT IN A MILDLY TORTUOUS AND MODERATELY CALCIFIED ARTERY. A 4.50 X 12MM SYNERGY XD DRUG-ELUTING STENT WAS ADVANCED FOR TREATMENT. HOWEVER, RESISTANCE WAS FELT DURING ADVANCEMENT AND THE STENT COULD NOT CROSS THE LESION. WHEN THE DEVICE WAS REMOVED, IT WAS NOTED THAT THE STENT STRUTS WERE STICKING UP ON THE PROXIMAL EDGE. THE PROCEDURE WAS COMPLETED WITH A 2.5X20MM SYNERGY XD STENT. THERE WERE NO PATIENT COMPLICATIONS NOR INJURIES REPORTED.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 12199592 ↗
Other Coronary drug-eluting stent devices
- SYNERGY™ H7493926038300Boston Scientific Corporation · Coronary drug-eluting stent8 deaths124 reports
- SYNERGY™ H7493926016300Boston Scientific Corporation · Coronary drug-eluting stent7 deaths106 reports
- SYNERGY™ H7493926020300Boston Scientific Corporation · Coronary drug-eluting stent9 deaths90 reports
- SYNERGY™ H7493926016250Boston Scientific Corporation · Coronary drug-eluting stent6 deaths82 reports
- XIENCE Sierra™ 1550350-33Abbott Vascular Inc. · Coronary drug-eluting stent1 recall32 reports
- Resolute Onyx™ RONYX30022UXMedtronic, Inc. · Coronary drug-eluting stent6 deaths76 reports
- SYNERGY™ H7493926024300Boston Scientific Corporation · Coronary drug-eluting stent3 deaths75 reports
- Resolute Onyx™ RONYX30015UXMedtronic, Inc. · Coronary drug-eluting stent3 deaths73 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page